Recent insights into the SWI/SNF complex and the molecular mechanism of hSNF5 deficiency in rhabdoid tumors.

Publisher: John Wiley & Sons Ltd Country of Publication: United States NLM ID: 101595310 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2045-7634 (Electronic) Linking ISSN: 20457634 NLM ISO Abbreviation: Cancer Med Subsets: MEDLINE

Original Publication: [Malden, MA] : John Wiley & Sons Ltd., c2012-

Transcription Factors*/genetics ; Transcription Factors*/metabolism ; Rhabdoid Tumor*/genetics ; Rhabdoid Tumor*/pathology; Humans ; DNA-Binding Proteins/genetics ; DNA-Binding Proteins/metabolism ; Chromosomal Proteins, Non-Histone/genetics ; Nucleosomes ; DNA ; Adenosine Triphosphate ; Chromatin Assembly and Disassembly

Genetic information encoded by DNA is packaged in the nucleus using the chromatin structure. The accessibility of transcriptional elements in DNA is controlled by the dynamic structural changes of chromatin for the appropriate regulation of gene transcription. Chromatin structure is regulated by two general mechanisms, one is histone modification and the other is chromatin remodeling in an ATP-dependent manner. Switch/sucrose nonfermentable (SWI/SNF) complexes utilize the energy from ATP hydrolysis to mobilize nucleosomes and remodel the chromatin structure, contributing to conformational changes in chromatin. Recently, the inactivation of encoding genes for subunits of the SWI/SNF complexes has been documented in a series of human cancers, accounting for up to almost 20% of all human cancers. For example, human SNF5 (hSNF5), the gene that encodes a subunit of the SWI/SNF complexes, is the sole mutation target that drives malignant rhabdoid tumors (MRT). Despite remarkably simple genomes, the MRT has highly malignant characteristics. As a key to understanding MRT tumorigenesis, it is necessary to fully examine the mechanism of chromatin remodeling by the SWI/SNF complexes. Herein, we review the current understanding of chromatin remodeling by focusing on SWI/SNF complexes. In addition, we describe the molecular mechanisms and influences of hSNF5 deficiency in rhabdoid tumors and the prospects for developing new therapeutic targets to overcome the epigenetic drive of cancer that is caused by abnormal chromatin remodeling.
(© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.)

Cancer Cell. 2014 Sep 8;26(3):309-317. (PMID: 25203320)
Cancer Res. 1999 Jan 1;59(1):74-9. (PMID: 9892189)
Cancer Cell. 2002 Nov;2(5):415-25. (PMID: 12450796)
Genes Chromosomes Cancer. 2014 Jun;53(6):475-86. (PMID: 24585572)
Mol Ther Oncolytics. 2022 Sep 19;27:14-25. (PMID: 36212776)
N Engl J Med. 2010 Oct 14;363(16):1532-43. (PMID: 20942669)
Cell. 1992 Feb 7;68(3):561-72. (PMID: 1346755)
Cancer. 1978 May;41(5):1937-48. (PMID: 206343)
J Clin Invest. 2012 Aug;122(8):2983-8. (PMID: 22797305)
Cancer Res. 2010 Mar 1;70(5):1854-65. (PMID: 20179200)
Int J Cancer. 2014 Aug 15;135(4):989-95. (PMID: 24420698)
Nat Commun. 2022 Sep 19;13(1):5478. (PMID: 36117191)
Nat Cell Biol. 2018 Dec;20(12):1410-1420. (PMID: 30397315)
Neuro Oncol. 2015 Jun;17(6):882-8. (PMID: 25688119)
J Clin Oncol. 2020 Apr 10;38(11):1175-1185. (PMID: 32105509)
Nature. 2022 May;605(7908):166-171. (PMID: 35477757)
Mol Cancer Ther. 2020 Oct;19(10):1992-2000. (PMID: 32847975)
Nat Med. 2010 Dec;16(12):1429-33. (PMID: 21076395)
JCI Insight. 2022 Aug 22;7(16):. (PMID: 35852858)
J Biol Chem. 2018 Mar 16;293(11):3892-3903. (PMID: 29374058)
BMC Res Notes. 2019 Feb 27;12(1):106. (PMID: 30813969)
Nat Genet. 1999 May;22(1):102-5. (PMID: 10319872)
Am J Med Genet C Semin Med Genet. 2014 Sep;166C(3):350-66. (PMID: 25169151)
EMBO J. 1996 Oct 1;15(19):5370-82. (PMID: 8895581)
J Immunol. 2007 Jun 1;178(11):7088-96. (PMID: 17513758)
Nat Rev Clin Oncol. 2020 Jul;17(7):435-448. (PMID: 32303701)
Prog Biophys Mol Biol. 2010 Jun-Jul;102(2-3):122-8. (PMID: 20493208)
Nat Genet. 2022 Jun;54(6):861-873. (PMID: 35681054)
Cell. 2013 Jan 17;152(1-2):248-61. (PMID: 23332759)
Mol Cancer Res. 2013 Mar;11(3):251-60. (PMID: 23364536)
Front Immunol. 2021 Aug 26;12:670040. (PMID: 34512623)
Nat Genet. 2013 Jan;45(1):12-7. (PMID: 23202128)
Cell. 2019 Nov 27;179(6):1342-1356.e23. (PMID: 31759698)
Nat Struct Mol Biol. 2007 Nov;14(11):989-96. (PMID: 17984961)
Nat Genet. 2017 Nov;49(11):1613-1623. (PMID: 28945250)
Nat Commun. 2019 Apr 23;10(1):1881. (PMID: 31015438)
J Invest Dermatol. 2021 Jun;141(6):1564-1572.e4. (PMID: 33333124)
J Cell Physiol. 2010 Nov;225(2):569-76. (PMID: 20506188)
Cancer Res. 2008 Mar 15;68(6):1667-74. (PMID: 18339845)
Nat Genet. 2012 Dec;44(12):1321-5. (PMID: 23143597)
Nat Rev Cancer. 2011 Jun 09;11(7):481-92. (PMID: 21654818)
Pediatr Blood Cancer. 2010 Jan;54(1):35-40. (PMID: 19798737)
Structure. 2015 Jul 7;23(7):1344-9. (PMID: 26073604)
Science. 1994 Dec 23;266(5193):2002-6. (PMID: 7801128)
Cell. 1992 Feb 7;68(3):573-83. (PMID: 1339306)
Cancer Genet. 2014 Sep;207(9):358-64. (PMID: 25246033)
Fam Cancer. 2021 Oct;20(4):305-316. (PMID: 33532948)
Clin Cancer Res. 2011 Jan 1;17(1):31-8. (PMID: 21208904)
Clin Cancer Res. 2014 Jan 1;20(1):21-7. (PMID: 24122795)
Nat Struct Biol. 2003 Feb;10(2):141-5. (PMID: 12524530)
Nature. 2017 Jul 19;547(7663):311-317. (PMID: 28726821)
Biochem Biophys Res Commun. 2011 Sep 16;413(1):62-8. (PMID: 21871868)
Clin Cancer Res. 2004 Sep 1;10(17):5940-8. (PMID: 15355927)
Virchows Arch. 2012 Oct;461(4):367-77. (PMID: 22915242)
Science. 2020 Feb 21;367(6480):875-881. (PMID: 32001526)
Cell. 1998 Nov 25;95(5):625-36. (PMID: 9845365)
Biochem Biophys Res Commun. 1999 Apr 21;257(3):886-90. (PMID: 10208879)
Proc Natl Acad Sci U S A. 2000 Dec 5;97(25):13796-800. (PMID: 11095756)
PLoS One. 2013 Jul 04;8(7):e66581. (PMID: 23861745)
Cancer Res. 2022 Mar 01;82(5):791-804. (PMID: 34987057)
Proc Natl Acad Sci U S A. 2013 May 7;110(19):7922-7. (PMID: 23620515)
Pediatr Blood Cancer. 2011 Jan;56(1):7-15. (PMID: 21108436)
J Mol Biol. 1984 Oct 5;178(4):853-68. (PMID: 6436497)
Nature. 1998 Jul 9;394(6689):203-6. (PMID: 9671307)
Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4152-7. (PMID: 9539705)
Neuron. 2007 Jul 19;55(2):201-15. (PMID: 17640523)
Nat Genet. 2013 Jul;45(7):791-8. (PMID: 23685749)
EMBO J. 2022 Dec 1;41(23):e110595. (PMID: 36305367)
EMBO J. 2002 Jan 15;21(1-2):31-42. (PMID: 11782423)
Curr Opin Cell Biol. 2019 Jun;58:95-104. (PMID: 30908980)
Cancer Med. 2023 Aug;12(15):16323-16336. (PMID: 37317642)
J Cell Biol. 1979 Nov;83(2 Pt 1):403-27. (PMID: 387806)
Oncogene. 2002 Aug 8;21(34):5193-203. (PMID: 12149641)
Cell. 2013 Aug 1;154(3):490-503. (PMID: 23911317)
Cancer Res. 2008 Aug 1;68(15):6154-61. (PMID: 18676838)
Cancer Res. 2011 May 1;71(9):3225-35. (PMID: 21521802)
Cancer Genet. 2014 Sep;207(9):373-8. (PMID: 24933152)
Cancer Cell. 2010 Oct 19;18(4):316-28. (PMID: 20951942)
Am J Hum Genet. 2010 Feb 12;86(2):279-84. (PMID: 20137775)
Clin Cancer Res. 2008 Feb 15;14(4):1192-9. (PMID: 18281554)
PLoS One. 2012;7(10):e47993. (PMID: 23110154)
Cancer Cell. 2017 Aug 14;32(2):185-203.e13. (PMID: 28810144)
Arch Virol. 2015 Dec;160(12):3085-91. (PMID: 26350979)
Nat Genet. 2012 May 27;44(7):760-4. (PMID: 22634756)
Nature. 2003 Jan 23;421(6921):448-53. (PMID: 12540921)
Nat Genet. 2014 May;46(5):427-9. (PMID: 24658001)
Clin Cancer Res. 2002 Nov;8(11):3461-7. (PMID: 12429635)
Genetics. 1984 Dec;108(4):845-58. (PMID: 6392017)
Clin Cancer Res. 2020 Nov 1;26(21):5701-5708. (PMID: 32709715)
Am J Surg Pathol. 2004 Nov;28(11):1485-91. (PMID: 15489652)
Oncol Rep. 2008 Mar;19(3):819-23. (PMID: 18288421)
Nature. 1997 Sep 18;389(6648):251-60. (PMID: 9305837)
J Cell Physiol. 2016 Sep;231(9):1932-40. (PMID: 26680268)
Eur Urol. 2016 Jun;69(6):1055-61. (PMID: 26433572)
Nucleic Acids Res. 1995 Apr 11;23(7):1127-32. (PMID: 7739891)
Clin Cancer Res. 2017 May 15;23(10):2433-2441. (PMID: 28432176)
Cell Res. 2011 Mar;21(3):396-420. (PMID: 21358755)
Cancer Sci. 2020 Mar;111(3):1008-1019. (PMID: 31922331)
Nat Genet. 2013 Jun;45(6):592-601. (PMID: 23644491)
Nat Genet. 2017 Feb;49(2):289-295. (PMID: 27941797)
Cancer Cell. 2016 Mar 14;29(3):379-393. (PMID: 26923874)
Science. 1994 Jul 1;265(5168):53-60. (PMID: 8016655)
J Biol Chem. 2002 Jun 21;277(25):22330-7. (PMID: 11950834)
Proc Natl Acad Sci U S A. 1994 Mar 1;91(5):1950-4. (PMID: 8127913)
J Pathol. 2012 Sep;228(1):20-30. (PMID: 22653804)
Proc Natl Acad Sci U S A. 1998 Feb 3;95(3):1120-5. (PMID: 9448295)
Brain Pathol. 2017 Jul;27(4):411-418. (PMID: 27380723)
Cell. 2020 Oct 29;183(3):802-817.e24. (PMID: 33053319)
J Biol Chem. 2010 Jan 22;285(4):2340-50. (PMID: 19910461)
JCI Insight. 2021 Sep 22;6(18):. (PMID: 34375311)
Cancer Res. 2009 Nov 1;69(21):8223-30. (PMID: 19843852)
Nat Struct Mol Biol. 2004 Nov;11(11):1037-43. (PMID: 15523479)
Mol Cell Biol. 2002 Aug;22(16):5975-88. (PMID: 12138206)
Trends Genet. 1992 Nov;8(11):387-91. (PMID: 1332230)
Cancer Cell. 2016 Dec 12;30(6):891-908. (PMID: 27960086)
Nature. 2011 Jan 27;469(7331):539-42. (PMID: 21248752)
Neuro Oncol. 2020 Jul 7;22(7):1006-1017. (PMID: 31883020)
Mol Cancer Res. 2014 Nov;12(11):1574-85. (PMID: 25009291)

Keywords: SWI/SNF complex; chromatin remodeling; hSNF5; molecular targets; rhabdoid tumor

0 (Transcription Factors)
0 (DNA-Binding Proteins)
0 (Chromosomal Proteins, Non-Histone)
0 (Nucleosomes)
9007-49-2 (DNA)
8L70Q75FXE (Adenosine Triphosphate)

Date Created: 20230615 Date Completed: 20230901 Latest Revision: 20230902

20231215

PMC10469780

10.1002/cam4.6255

37317642